31:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056390:0.958557:0.056390:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158618:-0.158618:0.000000:0.000000:0.000000:0.000000:0.242660:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
AbsOlute risK :@0.076191:0.087639:0.210347:0.087639:0.210347:0.067474:0.076191:0.067474:0.013674:0.010718:0.009609:0.015522:0.008131:0.011826:0.007761:0.009609:0.005174:0.010718:0.005174:0.009609:0.011457:0.005174
versus:@0.210328:0.087639:0.274635:0.087639:0.274635:0.067474:0.210328:0.067474:0.012935:0.009609:0.010718:0.009609:0.011826:0.009609
 AbsOlute benefit :@0.274635:0.087639:0.442423:0.087639:0.442423:0.067474:0.274635:0.067474:0.005174:0.013674:0.010718:0.009609:0.015522:0.008131:0.011826:0.007761:0.009609:0.005174:0.010718:0.009609:0.013674:0.009609:0.008870:0.005174:0.007761:0.005174
When  explaining the  merits  of  statin  use  to  a  patient, :@0.076190:0.103929:0.485130:0.103929:0.485130:0.088146:0.076190:0.088146:0.014514:0.009223:0.009827:0.009223:0.004188:0.002374:0.009827:0.007257:0.010311:0.003024:0.010326:0.003024:0.009223:0.003024:0.009223:0.010175:0.006577:0.005125:0.009223:0.009827:0.004188:0.002374:0.014182:0.009827:0.004551:0.003024:0.005125:0.005866:0.004188:0.002374:0.009903:0.004747:0.004188:0.002374:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.002374:0.009192:0.005866:0.009827:0.004188:0.002374:0.005125:0.009903:0.004188:0.002374:0.010326:0.004188:0.002374:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004188:0.004188
it is often helpful to spell out the concepts of absolute :@0.076190:0.118441:0.485115:0.118441:0.485115:0.102659:0.076190:0.102659:0.003024:0.005125:0.005609:0.003024:0.005866:0.005609:0.009903:0.004747:0.005125:0.009827:0.009223:0.005594:0.009223:0.009827:0.003024:0.010311:0.004747:0.009192:0.003024:0.005609:0.005125:0.009903:0.005594:0.005866:0.010311:0.009827:0.003024:0.003024:0.005609:0.009903:0.009192:0.005125:0.005594:0.005125:0.009223:0.009827:0.005594:0.009782:0.009903:0.009223:0.009782:0.009827:0.010311:0.005125:0.005866:0.005594:0.009903:0.004747:0.005594:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004188
versus:@0.076190:0.132954:0.119869:0.132954:0.119869:0.117171:0.076190:0.117171:0.008376:0.009827:0.004551:0.005866:0.009192:0.005866
 relative risk and absolute versus relative benefit.:@0.119869:0.132954:0.471402:0.132954:0.471402:0.117171:0.119869:0.117171:0.004188:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.004188:0.004551:0.003024:0.005866:0.007590:0.004188:0.010326:0.009223:0.010357:0.004188:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004188:0.008376:0.009827:0.004551:0.005866:0.009192:0.005866:0.004188:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.004188:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188
The absolute benefits of statin therapy depend on an :@0.090478:0.147467:0.485130:0.147467:0.485130:0.131684:0.090478:0.131684:0.006441:0.009223:0.009827:0.004309:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004309:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004309:0.009903:0.004747:0.004309:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004309:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004309:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.004309:0.009903:0.009223:0.004309:0.010326:0.009223:0.004188
individual’s  absolute risk of occlusive  vascular  events :@0.076190:0.161979:0.485145:0.161979:0.485145:0.146197:0.076190:0.146197:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.005307:0.005866:0.004188:0.003477:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.007650:0.004551:0.003024:0.005866:0.007590:0.007650:0.009903:0.004747:0.007650:0.009903:0.009782:0.009782:0.003024:0.009192:0.005866:0.003024:0.008376:0.009827:0.004188:0.003477:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.003477:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188
(which will be influenced by factors such as age, gen:@0.076190:0.176492:0.475923:0.176492:0.475923:0.160709:0.076190:0.160709:0.005579:0.012564:0.009223:0.003024:0.009782:0.009223:0.005337:0.012564:0.003024:0.003024:0.003024:0.005352:0.010311:0.009827:0.005337:0.003024:0.009223:0.003666:0.003666:0.009192:0.009827:0.009223:0.009782:0.009827:0.010357:0.005337:0.010311:0.008104:0.005337:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.005337:0.005866:0.009192:0.009782:0.009223:0.005337:0.010326:0.005866:0.005352:0.010326:0.010175:0.009827:0.004188:0.005337:0.010175:0.009827:0.009223
-:@0.475923:0.176492:0.480942:0.176492:0.480942:0.160709:0.475923:0.160709:0.005020
der, smoking status and concomitant  diseases  – e.g. :@0.076190:0.191004:0.485130:0.191004:0.485130:0.175222:0.076190:0.175222:0.010357:0.009827:0.004551:0.004188:0.007423:0.005866:0.014182:0.009903:0.007590:0.003024:0.009223:0.010175:0.007423:0.005866:0.005125:0.010326:0.005125:0.009192:0.005866:0.007423:0.010326:0.009223:0.010357:0.007423:0.009782:0.009903:0.009223:0.009782:0.009903:0.014182:0.003024:0.005125:0.010326:0.009223:0.005125:0.004188:0.003220:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005866:0.004188:0.003251:0.007560:0.007423:0.009827:0.004188:0.010175:0.004188:0.004188
hypertension  or  diabetes) and  the  reduction  in LDL :@0.076190:0.205517:0.485130:0.205517:0.485130:0.189734:0.076190:0.189734:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.004853:0.009903:0.004551:0.004188:0.004853:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005579:0.009056:0.010326:0.009223:0.010357:0.004188:0.004853:0.005125:0.009223:0.009827:0.004188:0.004853:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004853:0.003024:0.009223:0.009056:0.006985:0.011249:0.006985:0.004188
cholesterol  that  is achieved.  patients  with the  highest :@0.076190:0.220030:0.485130:0.220030:0.485130:0.204247:0.076190:0.204247:0.009782:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.004188:0.002525:0.005125:0.009223:0.010326:0.005125:0.004188:0.002525:0.003024:0.005866:0.006728:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.010357:0.004188:0.004188:0.002540:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.002525:0.012564:0.003024:0.005125:0.009223:0.006728:0.005125:0.009223:0.009827:0.004188:0.002525:0.009223:0.003024:0.010175:0.009223:0.009827:0.005866:0.005125:0.004188
absolute risk also benefit the most from statin treatment :@0.076190:0.234542:0.485145:0.234542:0.485145:0.218760:0.076190:0.218760:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004339:0.004551:0.003024:0.005866:0.007590:0.004339:0.010326:0.003024:0.005866:0.009903:0.004354:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004339:0.005125:0.009223:0.009827:0.004339:0.014182:0.009903:0.005866:0.005125:0.004339:0.004747:0.004551:0.009903:0.014182:0.004339:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004339:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
or,  to  put  it differently,  the  lowest  number  needed  to :@0.076190:0.249055:0.485130:0.249055:0.485130:0.233272:0.076190:0.233272:0.009903:0.004551:0.004188:0.004188:0.002404:0.005125:0.009903:0.004188:0.002404:0.010311:0.009192:0.005125:0.004188:0.002404:0.003024:0.005125:0.006607:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.004188:0.004188:0.002404:0.005125:0.009223:0.009827:0.004188:0.002404:0.003024:0.009903:0.012564:0.009827:0.005866:0.005125:0.004188:0.002404:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.004188:0.002404:0.009223:0.009827:0.009827:0.010357:0.009827:0.010357:0.004188:0.002404:0.005125:0.009903:0.004188
treat. For example, lowering LDL cholesterol by 2 mmol/L :@0.076190:0.263568:0.485145:0.263568:0.485145:0.247785:0.076190:0.247785:0.005125:0.004551:0.009827:0.010326:0.005125:0.004188:0.003205:0.007333:0.009903:0.004551:0.003205:0.009827:0.007257:0.010326:0.014182:0.010311:0.003024:0.009827:0.004188:0.003205:0.003024:0.009903:0.012564:0.009827:0.004551:0.003024:0.009223:0.010175:0.003205:0.006985:0.011249:0.006985:0.003205:0.009782:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.003205:0.010311:0.008104:0.003220:0.008376:0.003205:0.014182:0.014182:0.009903:0.003024:0.006607:0.006985:0.004188
with an effective low-cost statin regimen (e.g. atorvas-:@0.076190:0.278080:0.480942:0.278080:0.480942:0.262298:0.076190:0.262298:0.012564:0.003024:0.005125:0.009223:0.005125:0.010326:0.009223:0.005125:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005125:0.003024:0.009903:0.012564:0.005020:0.009782:0.009903:0.005866:0.005125:0.005125:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005125:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005110:0.005579:0.009827:0.004188:0.010175:0.004188:0.005110:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005020
tatin 40 mg daily) in 10 000 patients for five years would :@0.076190:0.292593:0.485130:0.292593:0.485130:0.276810:0.076190:0.276810:0.005125:0.010326:0.005125:0.003024:0.009223:0.004445:0.008376:0.008376:0.004460:0.014182:0.010175:0.004445:0.010357:0.010326:0.003024:0.003024:0.008104:0.005579:0.004460:0.003024:0.009223:0.004445:0.008376:0.008376:0.004475:0.008376:0.008376:0.008376:0.004460:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004445:0.004747:0.009903:0.004551:0.004445:0.003681:0.003681:0.008376:0.009827:0.004445:0.008104:0.009827:0.010326:0.004551:0.005866:0.004445:0.012564:0.009903:0.009192:0.003024:0.010357:0.004188
typically prevent  major  vascular events  from  occur-:@0.076190:0.307105:0.480957:0.307105:0.480957:0.291323:0.076190:0.291323:0.005125:0.008104:0.010311:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.008905:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004188:0.004702:0.014182:0.010326:0.003069:0.009903:0.004551:0.004188:0.004702:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.008905:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188:0.004702:0.004747:0.004551:0.009903:0.014182:0.004188:0.004702:0.009903:0.009782:0.009782:0.009192:0.004551:0.005020
ring in about 1 000 patients (10% absolute benefit) with :@0.076190:0.321618:0.485115:0.321618:0.485115:0.305835:0.076190:0.305835:0.004551:0.003024:0.009223:0.010175:0.004838:0.003024:0.009223:0.004838:0.010326:0.010311:0.009903:0.009192:0.005125:0.004823:0.008376:0.004838:0.008376:0.008376:0.008376:0.004838:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004838:0.005579:0.008376:0.008376:0.011717:0.004838:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004838:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005579:0.004823:0.012564:0.003024:0.005125:0.009223:0.004188
pre-existing occlusive vascular disease (secondary pre-:@0.076190:0.336131:0.480957:0.336131:0.480957:0.320348:0.076190:0.320348:0.010311:0.004551:0.009827:0.005020:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.004596:0.009903:0.009782:0.009782:0.003024:0.009192:0.005866:0.003024:0.008376:0.009827:0.004596:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010341:0.004551:0.004596:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004596:0.005579:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.004596:0.010311:0.004551:0.009827:0.005020
vention) and in 500 patients (5% absolute benefit) who :@0.076190:0.350643:0.485130:0.350643:0.485130:0.334861:0.076190:0.334861:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.005579:0.005020:0.010326:0.009223:0.010357:0.005020:0.003024:0.009223:0.005020:0.008376:0.008376:0.008376:0.005035:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005020:0.005579:0.008376:0.011717:0.005020:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.005020:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005579:0.005020:0.012564:0.009223:0.009903:0.004188
are at increased risk, but have not yet had a vascular :@0.076190:0.365156:0.485085:0.365156:0.485085:0.349373:0.076190:0.349373:0.010326:0.004551:0.009827:0.005518:0.010326:0.005125:0.005518:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005518:0.004551:0.003024:0.005866:0.007590:0.004188:0.005518:0.010311:0.009192:0.005125:0.005518:0.009223:0.010326:0.008376:0.009827:0.005518:0.009223:0.009903:0.005125:0.005518:0.008104:0.009827:0.005125:0.005518:0.009223:0.010326:0.010357:0.005518:0.010326:0.005518:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
event (primary prevention).  Long-term statin therapy :@0.076190:0.379669:0.485138:0.379571:0.485138:0.363788:0.076190:0.363886:0.009827:0.008376:0.009827:0.009223:0.005125:0.006350:0.005579:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.006350:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.005579:0.004188:0.009714:0.006350:0.006985:0.009903:0.009223:0.010175:0.005020:0.005125:0.009827:0.004551:0.014182:0.006335:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.006350:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.352184
14:@0.281048:0.374272:0.290764:0.374272:0.290764:0.365118:0.281048:0.365118:0.004858:0.004858
has been shown to reduce vascular disease risk during :@0.076183:0.394083:0.485123:0.394083:0.485123:0.378301:0.076183:0.378301:0.009223:0.010326:0.005866:0.005095:0.010311:0.009827:0.009827:0.009223:0.005095:0.005866:0.009223:0.009903:0.012564:0.009223:0.005080:0.005125:0.009903:0.005080:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005080:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005095:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005095:0.004551:0.003024:0.005866:0.007590:0.005095:0.010357:0.009192:0.004551:0.003024:0.009223:0.010175:0.004188
each year of continued use, so more substantial abso-:@0.076183:0.408596:0.480935:0.408596:0.480935:0.392813:0.076183:0.392813:0.009827:0.010326:0.009782:0.009223:0.005035:0.008104:0.009827:0.010326:0.004551:0.005050:0.009903:0.004747:0.005035:0.009782:0.009903:0.009223:0.005125:0.003024:0.009223:0.009192:0.009827:0.010357:0.005035:0.009192:0.005866:0.009827:0.004188:0.005050:0.005866:0.009903:0.005050:0.014182:0.009903:0.004551:0.009827:0.005035:0.005866:0.009192:0.010311:0.005866:0.005125:0.010326:0.009223:0.005125:0.003024:0.010326:0.003024:0.005050:0.010326:0.010311:0.005866:0.009903:0.005020
lute benefits would accrue with prolonged therapy.:@0.076183:0.423109:0.453388:0.423109:0.453388:0.407326:0.076183:0.407326:0.003024:0.009192:0.005125:0.009827:0.004188:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.012564:0.009903:0.009192:0.003024:0.010357:0.004188:0.010326:0.009782:0.009782:0.004551:0.009192:0.009827:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.010311:0.004551:0.009903:0.003024:0.009903:0.009223:0.010175:0.009827:0.010357:0.004188:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
To summarise, the potential major adverse effects of :@0.090471:0.437621:0.485153:0.437621:0.485153:0.421839:0.090471:0.421839:0.006441:0.009903:0.005307:0.005866:0.009192:0.014182:0.014182:0.010326:0.004551:0.003024:0.005866:0.009827:0.004188:0.005307:0.005125:0.009223:0.009827:0.005307:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.005307:0.014182:0.010326:0.003069:0.009903:0.004551:0.005307:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.005307:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005307:0.009903:0.004747:0.004188
long-term statin use are myopathy, NOD, and probably :@0.076183:0.452134:0.485123:0.452134:0.485123:0.436351:0.076183:0.436351:0.003024:0.009903:0.009223:0.010175:0.005020:0.005125:0.009827:0.004551:0.014182:0.004203:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004218:0.009192:0.005866:0.009827:0.004218:0.010326:0.004551:0.009827:0.004203:0.014182:0.008104:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188:0.004203:0.011188:0.013138:0.011249:0.004188:0.004203:0.010326:0.009223:0.010357:0.004218:0.010311:0.004551:0.009903:0.010311:0.010326:0.010311:0.003024:0.008104:0.004188
a small increase in the risk of haemorrhagic stroke. Treat-:@0.076183:0.466646:0.480950:0.466646:0.480950:0.450864:0.076183:0.450864:0.010326:0.003341:0.005866:0.014182:0.010326:0.003024:0.003024:0.003356:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.003341:0.003024:0.009223:0.003341:0.005125:0.009223:0.009827:0.003341:0.004551:0.003024:0.005866:0.007590:0.003341:0.009903:0.004747:0.003341:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.003326:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.003326:0.006441:0.004551:0.009827:0.010326:0.005125:0.005020
ing 10 000 patients for five years with an effective regi:@0.076183:0.481159:0.475916:0.481159:0.475916:0.465376:0.076183:0.465376:0.003024:0.009223:0.010175:0.005080:0.008376:0.008376:0.005095:0.008376:0.008376:0.008376:0.005080:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005080:0.004747:0.009903:0.004551:0.005080:0.003681:0.003681:0.008376:0.009827:0.005080:0.008104:0.009827:0.010326:0.004551:0.005866:0.005080:0.012564:0.003024:0.005125:0.009223:0.005080:0.010326:0.009223:0.005080:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005080:0.004551:0.009827:0.010175:0.003024
-:@0.475916:0.481159:0.480935:0.481159:0.480935:0.465376:0.475916:0.465376:0.005020
men (e.g. atorvastatin 40 mg daily) may cause about :@0.076183:0.495672:0.485123:0.495672:0.485123:0.479889:0.076183:0.479889:0.014182:0.009827:0.009223:0.005775:0.005579:0.009827:0.004188:0.010175:0.004188:0.005775:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005791:0.008376:0.008376:0.005791:0.014182:0.010175:0.005775:0.010357:0.010326:0.003024:0.003024:0.008104:0.005579:0.005791:0.014182:0.010326:0.008104:0.005791:0.009782:0.010326:0.009192:0.005866:0.009827:0.005791:0.010326:0.010311:0.009903:0.009192:0.005125:0.004188
five cases of myopathy (one of which might progress, :@0.076183:0.510184:0.485153:0.510184:0.485153:0.494402:0.076183:0.494402:0.003681:0.003681:0.008376:0.009827:0.005957:0.009782:0.010326:0.005866:0.009827:0.005866:0.005957:0.009903:0.004747:0.005957:0.014182:0.008104:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.005957:0.005579:0.009903:0.009223:0.009827:0.005957:0.009903:0.004747:0.005957:0.012564:0.009223:0.003024:0.009782:0.009223:0.005957:0.014182:0.003024:0.010175:0.009223:0.005125:0.005957:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.004188:0.004188
if the statin therapy is not stopped, to the more severe :@0.076183:0.524697:0.485153:0.524697:0.485153:0.508914:0.076183:0.508914:0.003024:0.004747:0.005171:0.005125:0.009223:0.009827:0.005171:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005171:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005171:0.003024:0.005866:0.005171:0.009223:0.009903:0.005125:0.005171:0.005866:0.005125:0.009903:0.010311:0.010311:0.009827:0.010357:0.004188:0.005171:0.005125:0.009903:0.005171:0.005125:0.009223:0.009827:0.005171:0.014182:0.009903:0.004551:0.009827:0.005171:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.004188
condition of rhabdomyolysis), 50-100 cases of NOD, and :@0.076183:0.539210:0.485108:0.539210:0.485108:0.523427:0.076183:0.523427:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.003583:0.009903:0.004747:0.003583:0.004551:0.009223:0.010326:0.010311:0.010357:0.009903:0.014182:0.008104:0.009903:0.003024:0.008104:0.005866:0.003024:0.005866:0.005579:0.004188:0.003598:0.008376:0.008376:0.005020:0.008376:0.008376:0.008376:0.003598:0.009782:0.010326:0.005866:0.009827:0.005866:0.003598:0.009903:0.004747:0.003583:0.011188:0.013138:0.011249:0.004188:0.003583:0.010326:0.009223:0.010357:0.004188
approximately 5-10 haemorrhagic  strokes.  However, :@0.076183:0.553722:0.485138:0.553722:0.485138:0.537940:0.076183:0.537940:0.010326:0.010311:0.010311:0.004551:0.009903:0.007257:0.003024:0.014182:0.010326:0.005125:0.009827:0.003024:0.008104:0.010205:0.008376:0.005020:0.008376:0.008376:0.010205:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.005987:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.005866:0.004188:0.004188:0.006002:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004188
any adverse impact of these side effects on major vas-:@0.076183:0.568235:0.480935:0.568235:0.480935:0.552452:0.076183:0.552452:0.010326:0.009223:0.008104:0.004551:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.004551:0.003024:0.014182:0.010311:0.010326:0.009782:0.005125:0.004551:0.009903:0.004747:0.004551:0.005125:0.009223:0.009827:0.005866:0.009827:0.004551:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004551:0.009903:0.009223:0.004551:0.014182:0.010326:0.003069:0.009903:0.004551:0.004551:0.008376:0.010326:0.005866:0.005020
cular events has already been taken into account in :@0.076183:0.582748:0.485138:0.582748:0.485138:0.566965:0.076183:0.566965:0.009782:0.009192:0.003024:0.010326:0.004551:0.006698:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.006698:0.009223:0.010326:0.005866:0.006698:0.010326:0.003024:0.004551:0.009827:0.010326:0.010357:0.008104:0.006698:0.010311:0.009827:0.009827:0.009223:0.006698:0.005125:0.010326:0.007590:0.009827:0.009223:0.006698:0.003024:0.009223:0.005125:0.009903:0.006698:0.010326:0.009782:0.009782:0.009903:0.009192:0.009223:0.005125:0.006698:0.003024:0.009223:0.004188
the estimates of the absolute benefits of statin therapy. :@0.076183:0.597260:0.482160:0.597260:0.482160:0.581478:0.076183:0.581478:0.005125:0.009223:0.009827:0.004188:0.009827:0.005866:0.005125:0.003024:0.014182:0.010326:0.005125:0.009827:0.005866:0.004188:0.009903:0.004747:0.004188:0.005125:0.009223:0.009827:0.004188:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.004188:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.009903:0.004747:0.004188:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004188
Overall, statins are still prescribed in inadequate dos-:@0.090471:0.611773:0.480950:0.611773:0.480950:0.595990:0.090471:0.595990:0.013138:0.008376:0.009827:0.004551:0.010326:0.003024:0.003024:0.004188:0.005050:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.005050:0.010326:0.004551:0.009827:0.005050:0.005866:0.005125:0.003024:0.003024:0.003024:0.005065:0.010311:0.004551:0.009827:0.005866:0.009782:0.004551:0.003024:0.010311:0.009827:0.010357:0.005050:0.003024:0.009223:0.005050:0.003024:0.009223:0.010326:0.010357:0.009827:0.010311:0.009192:0.010326:0.005125:0.009827:0.005050:0.010357:0.009903:0.005866:0.005020
es or not being taken by many patients at high cardio-:@0.076183:0.626285:0.480935:0.626285:0.480935:0.610503:0.076183:0.610503:0.009827:0.005866:0.004657:0.009903:0.004551:0.004657:0.009223:0.009903:0.005125:0.004657:0.010311:0.009827:0.003024:0.009223:0.010175:0.004657:0.005125:0.010326:0.007590:0.009827:0.009223:0.004657:0.010311:0.008104:0.004657:0.014182:0.010326:0.009223:0.008104:0.004657:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004657:0.010326:0.005125:0.004657:0.009223:0.003024:0.010175:0.009223:0.004657:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020
vascular risk. Although many factors contribute to this, :@0.076183:0.640798:0.485138:0.640798:0.485138:0.625015:0.076183:0.625015:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005775:0.004551:0.003024:0.005866:0.007590:0.004188:0.005775:0.011188:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.005760:0.014182:0.010326:0.009223:0.008104:0.005775:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.005775:0.009782:0.009903:0.009223:0.005125:0.004551:0.003024:0.010311:0.009192:0.005125:0.009827:0.005760:0.005125:0.009903:0.005775:0.005125:0.009223:0.003024:0.005866:0.004188:0.004188
unfounded  and often  irrational fear  of  statins is un-:@0.076183:0.655311:0.480965:0.655311:0.480965:0.639528:0.076183:0.639528:0.009192:0.009223:0.004747:0.009903:0.009192:0.009223:0.010357:0.009827:0.010357:0.004188:0.004551:0.010326:0.009223:0.010357:0.008754:0.009903:0.004747:0.005125:0.009827:0.009223:0.004188:0.004551:0.003024:0.004551:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.008754:0.004747:0.009827:0.010326:0.004551:0.004188:0.004551:0.009903:0.004747:0.004188:0.004551:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.008754:0.003024:0.005866:0.008754:0.009192:0.009223:0.005020
doubtedly a significant contributor. A negative percep:@0.076183:0.669823:0.475900:0.669823:0.475900:0.654041:0.076183:0.654041:0.010357:0.009903:0.009192:0.010311:0.005125:0.009827:0.010357:0.003024:0.008104:0.003916:0.010326:0.003916:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003916:0.009782:0.009903:0.009223:0.005125:0.004551:0.003024:0.010311:0.009192:0.005125:0.009903:0.004551:0.004188:0.003901:0.011188:0.003916:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.008376:0.009827:0.003916:0.010311:0.009827:0.004551:0.009782:0.009827:0.010311
-:@0.475900:0.669823:0.480920:0.669823:0.480920:0.654041:0.475900:0.654041:0.005020
tion of statins, or the expectation that adverse effects :@0.076183:0.684336:0.485138:0.684336:0.485138:0.668553:0.076183:0.668553:0.005125:0.003024:0.009903:0.009223:0.005866:0.009903:0.004747:0.005866:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.005866:0.009903:0.004551:0.005851:0.005125:0.009223:0.009827:0.005851:0.009827:0.007257:0.010311:0.009827:0.009782:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.005851:0.005125:0.009223:0.010326:0.005125:0.005866:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.005866:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188
will occur, may increase the likelihood of experiencing :@0.076183:0.698849:0.485138:0.698849:0.485138:0.683066:0.076183:0.683066:0.012564:0.003024:0.003024:0.003024:0.005292:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188:0.005261:0.014182:0.010326:0.008104:0.005277:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005277:0.005125:0.009223:0.009827:0.005261:0.003024:0.003024:0.007590:0.009827:0.003024:0.003024:0.009223:0.009903:0.009903:0.010357:0.005277:0.009903:0.004747:0.005277:0.009827:0.007257:0.010311:0.009827:0.004551:0.003024:0.009827:0.009223:0.009782:0.003024:0.009223:0.010175:0.004188
side effects. As doctors, we should not strengthen or en-:@0.076183:0.713361:0.480950:0.713361:0.480950:0.697579:0.076183:0.697579:0.005866:0.003024:0.010357:0.009827:0.003780:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.003780:0.011188:0.005866:0.003780:0.010357:0.009903:0.009782:0.005125:0.009903:0.004551:0.005866:0.004188:0.003765:0.012564:0.009827:0.003780:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003780:0.009223:0.009903:0.005125:0.003765:0.005866:0.005125:0.004551:0.009827:0.009223:0.010175:0.005125:0.009223:0.009827:0.009223:0.003765:0.009903:0.004551:0.003765:0.009827:0.009223:0.005020
courage this nocebo effect.  A relatively simple mes-:@0.076183:0.727874:0.480937:0.727750:0.480937:0.711968:0.076183:0.712091:0.009782:0.009903:0.009192:0.004551:0.010326:0.010175:0.009827:0.006184:0.005125:0.009223:0.003024:0.005866:0.006199:0.009223:0.009903:0.009782:0.009827:0.010311:0.009903:0.006184:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.009709:0.006184:0.011188:0.006184:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.003024:0.008104:0.006199:0.005866:0.003024:0.014182:0.010311:0.003024:0.009827:0.006199:0.014182:0.009827:0.005866:-0.098733
15:@0.288928:0.722452:0.298644:0.722452:0.298644:0.713298:0.288928:0.713298:0.004858:0.004858
sage for patients is that taking an adequate statin dose :@0.076186:0.742263:0.485125:0.742263:0.485125:0.726480:0.076186:0.726480:0.005866:0.010326:0.010175:0.009827:0.004097:0.004747:0.009903:0.004551:0.004097:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004097:0.003024:0.005866:0.004112:0.005125:0.009223:0.010326:0.005125:0.004097:0.005125:0.010326:0.007590:0.003024:0.009223:0.010175:0.004097:0.010326:0.009223:0.004097:0.010326:0.010357:0.009827:0.010311:0.009192:0.010326:0.005125:0.009827:0.004097:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004097:0.010357:0.009903:0.005866:0.009827:0.004188
can reduce their relative risk of having a heart attack :@0.076186:0.756776:0.485141:0.756776:0.485141:0.740993:0.076186:0.740993:0.009782:0.010326:0.009223:0.005821:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005821:0.005125:0.009223:0.009827:0.003024:0.004551:0.005821:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.005821:0.004551:0.003024:0.005866:0.007590:0.005821:0.009903:0.004747:0.005821:0.009223:0.010326:0.008376:0.003024:0.009223:0.010175:0.005821:0.010326:0.005821:0.009223:0.009827:0.010326:0.004551:0.005125:0.005821:0.010326:0.005125:0.005125:0.010326:0.009782:0.007590:0.004188
or stroke by approximately 50% and the higher their ab-:@0.076186:0.771288:0.480907:0.771288:0.480907:0.755506:0.076186:0.755506:0.009903:0.004551:0.004082:0.005866:0.005125:0.004551:0.009903:0.007590:0.009812:0.004082:0.010311:0.008104:0.004097:0.010326:0.010311:0.010311:0.004551:0.009903:0.007257:0.003024:0.014182:0.010326:0.005125:0.009827:0.003024:0.008104:0.004082:0.008376:0.008376:0.011717:0.004082:0.010326:0.009223:0.010357:0.004082:0.005125:0.009223:0.009827:0.004082:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004082:0.005125:0.009223:0.009827:0.003024:0.004551:0.004082:0.010326:0.010311:0.005020
solute risk, the greater the absolute benefits. The prov:@0.076186:0.785801:0.475903:0.785801:0.475903:0.770018:0.076186:0.770018:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.005609:0.004551:0.003024:0.005866:0.007590:0.004188:0.005624:0.005125:0.009223:0.009827:0.005609:0.010175:0.004551:0.009827:0.010326:0.005125:0.009827:0.004551:0.005609:0.005125:0.009223:0.009827:0.005609:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.005609:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.005609:0.006441:0.009223:0.009827:0.005609:0.010311:0.004551:0.009903:0.008376
-:@0.475903:0.785801:0.480922:0.785801:0.480922:0.770018:0.475903:0.770018:0.005020
en benefits of statins substantially outweigh their risk of :@0.076186:0.800314:0.485125:0.800314:0.485125:0.784531:0.076186:0.784531:0.009827:0.009223:0.005488:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.005488:0.009903:0.004747:0.005488:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.005503:0.005866:0.009192:0.010311:0.005866:0.005125:0.010326:0.009223:0.005125:0.003024:0.010326:0.003024:0.003024:0.008104:0.005503:0.009903:0.009192:0.005125:0.012564:0.009827:0.003024:0.010175:0.009223:0.005488:0.005125:0.009223:0.009827:0.003024:0.004551:0.005488:0.004551:0.003024:0.005866:0.007590:0.005503:0.009903:0.004747:0.004188
causing harm. Furthermore, many symptoms attributed :@0.076186:0.814826:0.485141:0.814826:0.485141:0.799044:0.076186:0.799044:0.009782:0.010326:0.009192:0.005866:0.003024:0.009223:0.010175:0.004793:0.009223:0.010326:0.004551:0.014182:0.004188:0.004778:0.007333:0.009192:0.004551:0.005125:0.009223:0.009827:0.004551:0.014182:0.009903:0.004551:0.009827:0.004188:0.004762:0.014182:0.010326:0.009223:0.008104:0.004793:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.004793:0.010326:0.005125:0.005125:0.004551:0.003024:0.010311:0.009192:0.005125:0.009827:0.010357:0.004188
to statins (e.g. muscle symptoms with a normal CK) are :@0.076186:0.829339:0.485141:0.829339:0.485141:0.813556:0.076186:0.813556:0.005125:0.009903:0.004747:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004762:0.005579:0.009827:0.004188:0.010175:0.004188:0.004747:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.004762:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.004762:0.012564:0.003024:0.005125:0.009223:0.004762:0.010326:0.004762:0.009223:0.009903:0.004551:0.014182:0.010326:0.003024:0.004762:0.012292:0.008935:0.005579:0.004762:0.010326:0.004551:0.009827:0.004188
often incidental and not causally related to the statin :@0.076186:0.843851:0.485141:0.843851:0.485141:0.828069:0.076186:0.828069:0.009903:0.004747:0.005125:0.009827:0.009223:0.006032:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.005125:0.010326:0.003024:0.006032:0.010326:0.009223:0.010357:0.006032:0.009223:0.009903:0.005125:0.006032:0.009782:0.010326:0.009192:0.005866:0.010326:0.003024:0.003024:0.008104:0.006048:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.010357:0.006032:0.005125:0.009903:0.006032:0.005125:0.009223:0.009827:0.006032:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188
therapy.  The  decision to  initiate  statin therapy  should :@0.076186:0.858364:0.485110:0.858364:0.485110:0.842581:0.076186:0.842581:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004188:0.002827:0.006441:0.009223:0.009827:0.004188:0.002827:0.010357:0.009827:0.009782:0.003024:0.005866:0.003024:0.009903:0.009223:0.007030:0.005125:0.009903:0.004188:0.002827:0.003024:0.009223:0.003024:0.005125:0.003024:0.010326:0.005125:0.009827:0.004188:0.002827:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.007030:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.002827:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188
be made after an informed discussion between the cli-:@0.076186:0.872877:0.480953:0.872877:0.480953:0.857094:0.076186:0.857094:0.010311:0.009827:0.004521:0.014182:0.010326:0.010357:0.009827:0.004521:0.010326:0.004747:0.005125:0.009827:0.004551:0.004521:0.010326:0.009223:0.004521:0.003024:0.009223:0.004747:0.009903:0.004551:0.014182:0.009827:0.010357:0.004521:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.003024:0.009903:0.009223:0.004521:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004521:0.005125:0.009223:0.009827:0.004521:0.009782:0.003024:0.003024:0.005020
nician and the patient about the risks and benefits of :@0.076186:0.887389:0.485156:0.887389:0.485156:0.871607:0.076186:0.871607:0.009223:0.003024:0.009782:0.003024:0.010326:0.009223:0.006123:0.010326:0.009223:0.010357:0.006123:0.005125:0.009223:0.009827:0.006123:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.006123:0.010326:0.010311:0.009903:0.009192:0.005125:0.006123:0.005125:0.009223:0.009827:0.006123:0.004551:0.003024:0.005866:0.007590:0.005866:0.006123:0.010326:0.009223:0.010357:0.006123:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.006123:0.009903:0.004747:0.004188
statin treatment, taking into account additional factors, :@0.076186:0.901902:0.485141:0.901902:0.485141:0.886119:0.076186:0.886119:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.003886:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.003886:0.005125:0.010326:0.007590:0.003024:0.009223:0.010175:0.003886:0.003024:0.009223:0.005125:0.009903:0.003886:0.010326:0.009782:0.009782:0.009903:0.009192:0.009223:0.005125:0.003886:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.003901:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.004188:0.004188
such  as  potential  benefits  from  lifestyle  modifications, :@0.076186:0.916415:0.485110:0.916415:0.485110:0.900632:0.076186:0.900632:0.005866:0.009192:0.009782:0.009223:0.004188:0.002948:0.010326:0.005866:0.004188:0.002963:0.010311:0.009903:0.005125:0.009827:0.009207:0.005125:0.003024:0.010326:0.003024:0.004188:0.002963:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.002948:0.004747:0.004551:0.009888:0.014182:0.004188:0.002948:0.003024:0.003024:0.004747:0.009827:0.005866:0.005125:0.008104:0.003024:0.009827:0.004188:0.002963:0.014182:0.009903:0.010357:0.003024:0.003681:0.003681:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
informed patient preference, comorbidities, polyphar-:@0.076186:0.930927:0.480953:0.930927:0.480953:0.915145:0.076186:0.915145:0.003024:0.009223:0.004747:0.009903:0.004551:0.014182:0.009827:0.010357:0.006365:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.006380:0.010311:0.004551:0.009827:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188:0.006365:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188:0.006380:0.010311:0.009903:0.003024:0.008104:0.010311:0.009223:0.010326:0.004551:0.005020
macy, general frailty and life expectancy.:@0.076186:0.945440:0.383843:0.945440:0.383843:0.929657:0.076186:0.929657:0.014182:0.010326:0.009782:0.008104:0.004188:0.004188:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.004188:0.004747:0.004551:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.010326:0.009223:0.010357:0.004188:0.003024:0.003024:0.004747:0.009827:0.004188:0.009827:0.007257:0.010311:0.009827:0.009782:0.005125:0.010326:0.009223:0.009782:0.008104:0.004188
tAKe-HOme messAGes:@0.519047:0.087643:0.722684:0.087643:0.722684:0.067478:0.519047:0.067478:0.007761:0.013674:0.011457:0.009609:0.007761:0.012566:0.015522:0.016631:0.009609:0.005174:0.016631:0.009609:0.009609:0.009609:0.013674:0.015522:0.009609:0.009609
The benefits of statins prescribed according to guide:@0.519047:0.103789:0.918780:0.103789:0.918780:0.088006:0.519047:0.088006:0.006441:0.009223:0.009827:0.006335:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.006335:0.009903:0.004747:0.006335:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.006350:0.010311:0.004551:0.009827:0.005866:0.009782:0.004551:0.003024:0.010311:0.009827:0.010357:0.006335:0.010326:0.009782:0.009782:0.009903:0.004551:0.010357:0.003024:0.009223:0.010175:0.006335:0.005125:0.009903:0.006335:0.010175:0.009192:0.003024:0.010357:0.009827
-:@0.918780:0.103789:0.923799:0.103789:0.923799:0.088006:0.918780:0.088006:0.005020
lines substantially outweigh the risk of adverse effects. :@0.519047:0.118151:0.928002:0.118151:0.928002:0.102369:0.519047:0.102369:0.003024:0.003024:0.009223:0.009827:0.005866:0.006169:0.005866:0.009192:0.010311:0.005866:0.005125:0.010326:0.009223:0.005125:0.003024:0.010326:0.003024:0.003024:0.008104:0.006169:0.009903:0.009192:0.005125:0.012564:0.009827:0.003024:0.010175:0.009223:0.006153:0.005125:0.009223:0.009827:0.006153:0.004551:0.003024:0.005866:0.007590:0.006169:0.009903:0.004747:0.006153:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.006169:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.004188
The  harm done  by negative statin publicity  and sub-:@0.519047:0.132514:0.923799:0.132514:0.923799:0.116731:0.519047:0.116731:0.006441:0.009223:0.009827:0.004188:0.002857:0.009223:0.010326:0.004551:0.014182:0.007061:0.010357:0.009903:0.009223:0.009827:0.004188:0.002857:0.010311:0.008104:0.007061:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.008376:0.009827:0.007061:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.007061:0.010311:0.009192:0.010311:0.003024:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188:0.002888:0.010326:0.009223:0.010357:0.007061:0.005866:0.009192:0.010311:0.005020
sequent treatment discontinuation exceeds any harm :@0.519047:0.146877:0.927987:0.146877:0.927987:0.131094:0.519047:0.131094:0.005866:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.006214:0.005125:0.004551:0.009827:0.010326:0.005125:0.014167:0.009827:0.009223:0.005125:0.006214:0.010357:0.003024:0.005866:0.009782:0.009903:0.009223:0.005125:0.003024:0.009223:0.009192:0.010326:0.005125:0.003024:0.009903:0.009223:0.006214:0.009827:0.007257:0.009782:0.009827:0.009827:0.010357:0.005866:0.006214:0.010326:0.009223:0.008104:0.006229:0.009223:0.010326:0.004551:0.014182:0.004188
done by statins themselves. statins should be prescribed :@0.519047:0.161239:0.927987:0.161239:0.927987:0.145456:0.519047:0.145456:0.010357:0.009903:0.009223:0.009827:0.003538:0.010311:0.008104:0.003538:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.003538:0.005125:0.009223:0.009827:0.014182:0.005866:0.009827:0.003024:0.008376:0.009827:0.005866:0.004188:0.003568:0.007529:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.003553:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003538:0.010311:0.009827:0.003538:0.010311:0.004551:0.009827:0.005866:0.009782:0.004551:0.003024:0.010311:0.009827:0.010357:0.004188
with a positive attitude as patients who fear statins are :@0.519047:0.175602:0.927987:0.175602:0.927987:0.159819:0.519047:0.159819:0.012564:0.003024:0.005125:0.009223:0.005050:0.010326:0.005065:0.010311:0.009903:0.005866:0.003024:0.005125:0.003024:0.008376:0.009827:0.005065:0.010326:0.005125:0.005125:0.003024:0.005125:0.009192:0.010357:0.009827:0.005050:0.010326:0.005866:0.005065:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005050:0.012564:0.009223:0.009903:0.005050:0.004747:0.009827:0.010326:0.004551:0.005050:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.005065:0.010326:0.004551:0.009827:0.004188
more likely to experience side effects.:@0.519047:0.189964:0.794713:0.189964:0.794713:0.174182:0.519047:0.174182:0.014182:0.009903:0.004551:0.009827:0.004188:0.003024:0.003024:0.007590:0.009827:0.003024:0.008104:0.004188:0.005125:0.009903:0.004188:0.009827:0.007257:0.010311:0.009827:0.004551:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188:0.005866:0.003024:0.010357:0.009827:0.004188:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188
statins are no panacea; neither are they poison. They :@0.533335:0.204327:0.927987:0.204327:0.927987:0.188544:0.533335:0.188544:0.007529:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004052:0.010326:0.004551:0.009827:0.004037:0.009223:0.009903:0.004037:0.010311:0.010326:0.009223:0.010326:0.009782:0.009827:0.010326:0.004188:0.004037:0.009223:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004037:0.010326:0.004551:0.009827:0.004037:0.005125:0.009223:0.009827:0.008104:0.004037:0.010311:0.009903:0.003024:0.005866:0.009903:0.009223:0.004188:0.004037:0.006441:0.009223:0.009827:0.008104:0.004188
are one of the pharmaceutical pillars of cardiovascular :@0.519047:0.218689:0.928002:0.218689:0.928002:0.202907:0.519047:0.202907:0.010326:0.004551:0.009827:0.004158:0.009903:0.009223:0.009827:0.004158:0.009903:0.004747:0.004158:0.005125:0.009223:0.009827:0.004158:0.010311:0.009223:0.010326:0.004551:0.014182:0.010326:0.009782:0.009827:0.009192:0.005125:0.003024:0.009782:0.010326:0.003024:0.004158:0.010311:0.003024:0.003024:0.003024:0.010326:0.004551:0.005866:0.004173:0.009903:0.004747:0.004158:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
risk reduction and are an essential component of a well-:@0.519047:0.233052:0.923799:0.233052:0.923799:0.217269:0.519047:0.217269:0.004551:0.003024:0.005866:0.007590:0.003402:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003387:0.010326:0.009223:0.010357:0.003402:0.010326:0.004551:0.009827:0.003387:0.010326:0.009223:0.003402:0.009827:0.005866:0.005866:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.003402:0.009782:0.009903:0.014182:0.010311:0.009903:0.009223:0.009827:0.009223:0.005125:0.003387:0.009903:0.004747:0.003387:0.010326:0.003402:0.012564:0.009827:0.003024:0.003024:0.005020
designed therapeutic plan for patients at high cardio-:@0.519047:0.247414:0.923814:0.247414:0.923814:0.231632:0.519047:0.231632:0.010357:0.009827:0.005866:0.003024:0.010175:0.009223:0.009827:0.010357:0.005549:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.009827:0.009192:0.005125:0.003024:0.009782:0.005549:0.010311:0.003024:0.010326:0.009223:0.005549:0.004747:0.009903:0.004551:0.005534:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005549:0.010326:0.005125:0.005549:0.009223:0.003024:0.010175:0.009223:0.005549:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020
vascular risk.:@0.519047:0.261777:0.609898:0.261777:0.609898:0.245994:0.519047:0.245994:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.004551:0.003024:0.005866:0.007590:0.004188
referenCes:@0.519047:0.294948:0.625485:0.294948:0.625485:0.274783:0.519047:0.274783:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.519047:0.307099:0.532077:0.307099:0.532077:0.294824:0.519047:0.294824:0.006515:0.003257:0.003257
Goldstein JL, Brown Ms. Regulation of the mevalonate pathway. :@0.544247:0.307099:0.927070:0.307099:0.927070:0.294824:0.544247:0.294824:0.010254:0.007702:0.002352:0.008055:0.004563:0.003986:0.007644:0.002352:0.007173:0.004998:0.005668:0.005433:0.003257:0.004986:0.006750:0.003540:0.007702:0.009772:0.007173:0.004998:0.010807:0.005856:0.003257:0.004998:0.007138:0.007644:0.007914:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.004986:0.007702:0.003692:0.004998:0.003986:0.007173:0.007644:0.004986:0.011030:0.007644:0.006515:0.008032:0.002352:0.007702:0.007173:0.008032:0.003986:0.007644:0.004998:0.008020:0.008032:0.003986:0.007173:0.009772:0.008032:0.006303:0.003257:0.003257
Nature. :@0.544247:0.318261:0.589814:0.318261:0.589814:0.305986:0.544247:0.305986:0.008702:0.008032:0.003986:0.007150:0.003540:0.007644:0.003257:0.003257
1990;343(6257):425-30.:@0.589803:0.318261:0.716391:0.318261:0.716391:0.305986:0.589803:0.305986:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2. :@0.519047:0.329423:0.532077:0.329423:0.532077:0.317147:0.519047:0.317147:0.006515:0.003257:0.003257
Golomb BA, Kane T, Dimsdale JE. severe irritability associated with :@0.544247:0.329423:0.927070:0.329423:0.927070:0.317147:0.544247:0.317147:0.010254:0.007702:0.002352:0.007702:0.011030:0.008020:0.003763:0.006750:0.008702:0.003257:0.003763:0.006950:0.008032:0.007173:0.007644:0.003763:0.005009:0.003257:0.003763:0.008749:0.002352:0.011030:0.004563:0.008055:0.008032:0.002352:0.007644:0.003775:0.005668:0.006303:0.003257:0.003763:0.005856:0.007644:0.006515:0.007644:0.003540:0.007644:0.003763:0.002352:0.003540:0.003540:0.002352:0.003986:0.008032:0.008020:0.002352:0.002352:0.002352:0.003986:0.006303:0.003775:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.003775:0.009772:0.002352:0.003986:0.007173:0.003257
statin cholesterol-lowering drugs. :@0.544247:0.340585:0.733207:0.340585:0.733207:0.328309:0.544247:0.328309:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257:0.007608:0.007173:0.007702:0.002352:0.007644:0.004563:0.003986:0.007644:0.003540:0.007702:0.002352:0.003904:0.002352:0.007702:0.009772:0.007644:0.003540:0.002352:0.007173:0.007914:0.003257:0.008055:0.003540:0.007150:0.007914:0.004563:0.003257:0.003257
QJM.:@0.733183:0.340585:0.763158:0.340585:0.763158:0.328309:0.733183:0.328309:0.010242:0.005668:0.010807:0.003257
 2004; 97(4):229-35:@0.763158:0.340585:0.866945:0.340585:0.866945:0.328309:0.763158:0.328309:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515
3. :@0.519047:0.351747:0.532077:0.351747:0.532077:0.339471:0.519047:0.339471:0.006515:0.003257:0.003257
News C. 76. :@0.544247:0.351747:0.613803:0.351747:0.613803:0.339471:0.544247:0.339471:0.008702:0.007644:0.009772:0.004563:0.003257:0.009560:0.003257:0.003257:0.006515:0.006515:0.003257:0.003257
CGS News. :@0.613803:0.351747:0.679926:0.351747:0.679926:0.339471:0.613803:0.339471:0.009560:0.010254:0.005856:0.003257:0.008702:0.007644:0.009772:0.004563:0.003257:0.003257
2005:07 March, 2005.:@0.679914:0.351747:0.798506:0.351747:0.798506:0.339471:0.679914:0.339471:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.010807:0.008032:0.003540:0.007608:0.007173:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
4. :@0.519047:0.362908:0.532077:0.362908:0.532077:0.350633:0.519047:0.350633:0.006515:0.003257:0.003257
Graveline D. Lipitor: Thief of memory: statin drugs and the misguid-:@0.544247:0.362908:0.923801:0.362908:0.923801:0.350633:0.544247:0.350633:0.010254:0.003540:0.008032:0.006515:0.007644:0.002352:0.002352:0.007173:0.007644:0.003563:0.008749:0.003257:0.003563:0.005433:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.003257:0.003563:0.005009:0.007173:0.002352:0.007644:0.003692:0.003563:0.007702:0.003692:0.003563:0.011030:0.007644:0.011030:0.007702:0.003540:0.006303:0.003257:0.003575:0.005856:0.003986:0.008032:0.003986:0.002352:0.007173:0.003563:0.008055:0.003540:0.007150:0.007914:0.004563:0.003563:0.008032:0.007173:0.008055:0.003563:0.003986:0.007173:0.007644:0.003563:0.011030:0.002352:0.004563:0.007914:0.007150:0.002352:0.008055:0.003904
ed war on cholesterol. Pennsylvania: Infinity Publishing; 2006.:@0.544247:0.374070:0.885971:0.374070:0.885971:0.361795:0.544247:0.361795:0.007644:0.008055:0.003257:0.009772:0.008032:0.003540:0.003257:0.007702:0.007173:0.003257:0.007608:0.007173:0.007702:0.002352:0.007644:0.004563:0.003986:0.007644:0.003540:0.007702:0.002352:0.003257:0.003257:0.006961:0.007644:0.007173:0.007173:0.004563:0.006303:0.002352:0.006515:0.008032:0.007173:0.002352:0.008032:0.003257:0.003257:0.002658:0.007173:0.002863:0.002863:0.007173:0.002352:0.003986:0.006303:0.003257:0.006961:0.007150:0.008020:0.002352:0.002352:0.004563:0.007173:0.002352:0.007173:0.007914:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
5. :@0.519047:0.385232:0.532077:0.385232:0.532077:0.372957:0.519047:0.372957:0.006515:0.003257:0.003257
Yang CC, Jick ss, Jick H. Lipid-lowering drugs and the risk of depres-:@0.544247:0.385232:0.923812:0.385232:0.923812:0.372957:0.544247:0.372957:0.006961:0.008032:0.007173:0.007914:0.002893:0.009560:0.009560:0.003257:0.002905:0.005668:0.002352:0.007608:0.005903:0.002905:0.005856:0.005856:0.003257:0.002905:0.005668:0.002352:0.007608:0.005903:0.002905:0.008032:0.003257:0.002905:0.005433:0.002352:0.008020:0.002352:0.008055:0.003904:0.002352:0.007702:0.009772:0.007644:0.003540:0.002352:0.007173:0.007914:0.002905:0.008055:0.003540:0.007150:0.007914:0.004563:0.002905:0.008032:0.007173:0.008055:0.002905:0.003986:0.007173:0.007644:0.002893:0.003540:0.002352:0.004563:0.005903:0.002905:0.007702:0.003692:0.002893:0.008055:0.007644:0.008020:0.003540:0.007644:0.004563:0.003904
sion and suicidal behavior. :@0.544247:0.396394:0.699023:0.396394:0.699023:0.384119:0.544247:0.384119:0.004563:0.002352:0.007702:0.007173:0.003257:0.008032:0.007173:0.008055:0.003257:0.004563:0.007150:0.002352:0.007608:0.002352:0.008055:0.008032:0.002352:0.003257:0.008020:0.007644:0.007173:0.008032:0.006515:0.002352:0.007702:0.003540:0.003257:0.003257
Arch Intern Med.:@0.699023:0.396394:0.794496:0.396394:0.794496:0.384119:0.699023:0.384119:0.008702:0.003540:0.007608:0.007173:0.003257:0.002658:0.007173:0.003986:0.007644:0.003540:0.007173:0.003257:0.010807:0.007644:0.008055:0.003257
 2003; 163:1926. :@0.794472:0.396394:0.885677:0.396394:0.885677:0.384119:0.794472:0.384119:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
6. :@0.519047:0.407556:0.532077:0.407556:0.532077:0.395281:0.519047:0.395281:0.006515:0.003257:0.003257
Richardson K, schoen M, :@0.544247:0.407556:0.687252:0.407556:0.687252:0.395281:0.544247:0.395281:0.007138:0.002352:0.007608:0.007173:0.008032:0.003540:0.008055:0.004563:0.007702:0.007173:0.002999:0.006950:0.003257:0.002999:0.005856:0.007608:0.007173:0.007702:0.007644:0.007173:0.002987:0.010807:0.003257:0.003257
et al.:@0.686993:0.407556:0.715262:0.407556:0.715262:0.395281:0.686993:0.395281:0.007644:0.003986:0.002999:0.008032:0.002352:0.003257
 statins and cognitive function: A sys-:@0.715262:0.407556:0.923824:0.407556:0.923824:0.395281:0.715262:0.395281:0.002999:0.005856:0.003986:0.008032:0.003986:0.002352:0.007173:0.004563:0.002999:0.008032:0.007173:0.008055:0.002999:0.007608:0.007702:0.007914:0.007173:0.002352:0.003986:0.002352:0.006515:0.007644:0.002999:0.003692:0.007150:0.007173:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.002987:0.008702:0.002999:0.004563:0.006303:0.004563:0.003904
tematic review. :@0.544247:0.418718:0.636122:0.418718:0.636122:0.406442:0.544247:0.406442:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003257:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.003257
Ann Intern Med. :@0.636111:0.418718:0.730867:0.418718:0.730867:0.406442:0.636111:0.406442:0.008702:0.007173:0.007173:0.003257:0.002658:0.007173:0.003986:0.007644:0.003540:0.007173:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2013 Nov 19;159:688-97.:@0.730843:0.418718:0.865157:0.418718:0.865157:0.406442:0.730843:0.406442:0.006515:0.006515:0.006515:0.006515:0.003257:0.008702:0.007702:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
7. :@0.519036:0.429880:0.532065:0.429880:0.532065:0.417604:0.519036:0.417604:0.006515:0.003257:0.003257
Muldoon MF, Barger  sD, Ryan CM, :@0.544236:0.429880:0.751916:0.429880:0.751916:0.417604:0.544236:0.417604:0.010807:0.007150:0.002352:0.008055:0.007702:0.007702:0.007173:0.005233:0.010807:0.005703:0.003257:0.005233:0.006750:0.008032:0.003540:0.007914:0.007644:0.003540:0.003257:0.001976:0.005856:0.008749:0.003257:0.005233:0.007138:0.006303:0.008032:0.007173:0.005233:0.009560:0.010807:0.003257:0.003257
et al. :@0.753891:0.429880:0.787652:0.429880:0.787652:0.417604:0.753891:0.417604:0.007644:0.003986:0.005233:0.008032:0.002352:0.003257:0.003257
Effects of lovastatin  on :@0.789628:0.429880:0.927046:0.429880:0.927046:0.417604:0.789628:0.417604:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.005233:0.007702:0.003692:0.005233:0.002352:0.007702:0.006515:0.008032:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257:0.001987:0.007702:0.007173:0.003257
cognitive function  and psychological well-being. :@0.544236:0.441042:0.846613:0.441042:0.846613:0.428766:0.544236:0.428766:0.007608:0.007702:0.007914:0.007173:0.002352:0.003986:0.002352:0.006515:0.007644:0.008431:0.003692:0.007150:0.007173:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.005162:0.008032:0.007173:0.008055:0.008431:0.008020:0.004563:0.006303:0.007608:0.007173:0.007702:0.002352:0.007702:0.007914:0.002352:0.007608:0.008032:0.002352:0.008431:0.009772:0.007644:0.002352:0.002352:0.003904:0.008020:0.007644:0.002352:0.007173:0.007914:0.003257:0.003257
Am  J Med. :@0.851787:0.441042:0.927058:0.441042:0.927058:0.428766:0.851787:0.428766:0.008702:0.011030:0.003257:0.005162:0.005668:0.008431:0.010807:0.007644:0.008055:0.003257:0.003257
2000;108(7)538-546.:@0.544236:0.452204:0.654537:0.452204:0.654537:0.439928:0.544236:0.439928:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
8. :@0.519036:0.463365:0.532065:0.463365:0.532065:0.451090:0.519036:0.451090:0.006515:0.003257:0.003257
Muldoon MF RC, sereika sM, :@0.544236:0.463365:0.711981:0.463365:0.711981:0.451090:0.544236:0.451090:0.010807:0.007150:0.002352:0.008055:0.007702:0.007702:0.007173:0.004045:0.010807:0.005703:0.004045:0.007138:0.009560:0.003257:0.004057:0.005856:0.007644:0.003540:0.007644:0.002352:0.005903:0.008032:0.004045:0.005856:0.010807:0.003257:0.003257
et al.:@0.712769:0.463365:0.742085:0.463365:0.742085:0.451090:0.712769:0.451090:0.007644:0.003986:0.004045:0.008032:0.002352:0.003257
 Randomized trial of the effects :@0.742085:0.463365:0.927046:0.463365:0.927046:0.451090:0.742085:0.451090:0.004045:0.007138:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.004045:0.003986:0.003540:0.002352:0.008032:0.002352:0.004057:0.007702:0.003692:0.004045:0.003986:0.007173:0.007644:0.004045:0.007644:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.003257
of  simvastatin  on  cognitive  functioning  in  hypercholesterolemic :@0.544236:0.474527:0.927046:0.474527:0.927046:0.462252:0.544236:0.462252:0.007702:0.003692:0.003257:0.003422:0.004563:0.002352:0.011030:0.006515:0.008032:0.004574:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257:0.003422:0.007702:0.007173:0.003257:0.003422:0.007608:0.007702:0.007914:0.007173:0.002352:0.003986:0.002352:0.006515:0.007644:0.003257:0.003422:0.003692:0.007150:0.007173:0.007608:0.003986:0.002352:0.007702:0.007161:0.002352:0.007173:0.007914:0.003257:0.003422:0.002352:0.007173:0.003257:0.003422:0.007173:0.006303:0.008020:0.007644:0.003540:0.007608:0.007173:0.007702:0.002352:0.007644:0.004563:0.003986:0.007644:0.003540:0.007702:0.002352:0.007644:0.011030:0.002352:0.007608:0.003257
adults. :@0.544236:0.485689:0.584887:0.485689:0.584887:0.473414:0.544236:0.473414:0.008032:0.008055:0.007150:0.002352:0.003986:0.004563:0.003257:0.003257
Am J Med. :@0.584887:0.485689:0.649822:0.485689:0.649822:0.473414:0.584887:0.473414:0.008702:0.011030:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2004;117(11):823-829.:@0.649810:0.485689:0.769884:0.485689:0.769884:0.473414:0.649810:0.473414:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
9. :@0.519036:0.496851:0.532065:0.496851:0.532065:0.484576:0.519036:0.484576:0.006515:0.003257:0.003257
swiger KJ, Manalac RJ, Blumenthal Rs, :@0.544236:0.496851:0.766897:0.496851:0.766897:0.484576:0.544236:0.484576:0.005856:0.009772:0.002352:0.007914:0.007644:0.003540:0.003692:0.006950:0.005668:0.003257:0.003692:0.010807:0.008032:0.007173:0.008032:0.002352:0.008032:0.007608:0.003692:0.007138:0.005668:0.003257:0.003692:0.006750:0.002352:0.007150:0.011030:0.007644:0.007173:0.003986:0.007173:0.008032:0.002352:0.003692:0.007138:0.005856:0.003257:0.003257
et al.:@0.767332:0.496851:0.796295:0.496851:0.796295:0.484576:0.767332:0.484576:0.007644:0.003986:0.003692:0.008032:0.002352:0.003257
 statins and cognition: :@0.796295:0.496851:0.927058:0.496851:0.927058:0.484576:0.796295:0.484576:0.003692:0.005856:0.003986:0.008032:0.003986:0.002352:0.007173:0.004563:0.003692:0.008032:0.007173:0.008055:0.003692:0.007608:0.007702:0.007914:0.007173:0.002352:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
A systematic review and meta-analysis of short- and long-term cog-:@0.544236:0.508013:0.923812:0.508013:0.923812:0.495738:0.544236:0.495738:0.008702:0.002693:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.002693:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.002693:0.008032:0.007173:0.008055:0.002693:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.002705:0.007702:0.003692:0.002693:0.004563:0.007173:0.007702:0.003540:0.003986:0.003904:0.002681:0.008032:0.007173:0.008055:0.002693:0.002352:0.007702:0.007173:0.007914:0.003904:0.003986:0.007644:0.003540:0.011030:0.002681:0.007608:0.007702:0.007914:0.003904
nitive effects. :@0.544236:0.519175:0.622858:0.519175:0.622858:0.506899:0.544236:0.506899:0.007173:0.002352:0.003986:0.002352:0.006515:0.007644:0.003257:0.007644:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.003257:0.003257
Mayo Clin Proc.:@0.622858:0.519175:0.712722:0.519175:0.712722:0.506899:0.622858:0.506899:0.010807:0.008032:0.006303:0.007702:0.003257:0.009560:0.002352:0.002352:0.007173:0.003257:0.006961:0.003540:0.007702:0.007608:0.003257
 2013;88(11):1213-21.:@0.712710:0.519175:0.829527:0.519175:0.829527:0.506899:0.712710:0.506899:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
10.  Nissen sE, Dent-Acosta RE, Rosenson Rs, :@0.519036:0.530337:0.779726:0.530337:0.779726:0.518061:0.519036:0.518061:0.006515:0.006515:0.003257:0.003257:0.005656:0.008702:0.002352:0.004563:0.004563:0.007644:0.007173:0.004633:0.005856:0.006303:0.003257:0.004633:0.008749:0.007644:0.007173:0.003986:0.003904:0.008702:0.007608:0.007702:0.004563:0.003986:0.008032:0.004633:0.007138:0.006303:0.003257:0.004633:0.007138:0.007702:0.004563:0.007644:0.007173:0.004563:0.007702:0.007173:0.004633:0.007138:0.005856:0.003257:0.003257
et al. :@0.781102:0.530337:0.814263:0.530337:0.814263:0.518061:0.781102:0.518061:0.007644:0.003986:0.004633:0.008032:0.002352:0.003257:0.003257
GAUss-3 Investiga-:@0.815639:0.530337:0.923801:0.530337:0.923801:0.518061:0.815639:0.518061:0.010254:0.008702:0.007702:0.005856:0.005856:0.003904:0.006515:0.004633:0.002658:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003904
tors.  Efficacy  and  tolerability  of  evolocumab  vs  ezetimibe  in  pa:@0.544236:0.541499:0.919873:0.541499:0.919873:0.529223:0.544236:0.529223:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257:0.002070:0.006303:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.003257:0.002070:0.008032:0.007173:0.008055:0.003257:0.002070:0.003986:0.007702:0.002352:0.007644:0.003540:0.008032:0.008020:0.002352:0.002352:0.002352:0.003986:0.006303:0.003257:0.002081:0.007702:0.003692:0.003257:0.002070:0.007644:0.006515:0.007702:0.002352:0.007702:0.007608:0.007150:0.011030:0.008032:0.008020:0.003257:0.002070:0.006515:0.004563:0.003257:0.002081:0.007644:0.004998:0.007644:0.003986:0.002352:0.011030:0.002352:0.008020:0.007644:0.003257:0.002070:0.002352:0.007173:0.003257:0.002070:0.008020:0.008032
-:@0.919873:0.541499:0.923777:0.541499:0.923777:0.529223:0.919873:0.529223:0.003904
tients with muscle-related statin intolerance:  The GAUss-3 rand-:@0.544236:0.552660:0.923801:0.552660:0.923801:0.540385:0.544236:0.540385:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.006174:0.009772:0.002352:0.003986:0.007173:0.006174:0.011030:0.007150:0.004563:0.007608:0.002352:0.007644:0.003904:0.003540:0.007644:0.002352:0.008032:0.003986:0.007644:0.008055:0.006174:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.006174:0.002352:0.007173:0.003986:0.007702:0.002352:0.007644:0.003540:0.008032:0.007173:0.007608:0.007644:0.003257:0.003257:0.002905:0.005009:0.007173:0.007644:0.006174:0.010254:0.008702:0.007702:0.005856:0.005856:0.003904:0.006515:0.006174:0.003540:0.008032:0.007173:0.008055:0.003904
omized clinical trial. :@0.544236:0.563822:0.659135:0.563822:0.659135:0.551547:0.544236:0.551547:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003257:0.003986:0.003540:0.002352:0.008032:0.002352:0.003257:0.003257
JAMA. :@0.659135:0.563822:0.699528:0.563822:0.699528:0.551547:0.659135:0.551547:0.005668:0.008702:0.010807:0.008702:0.003257:0.003257
2016;315(15):1580-90. :@0.699517:0.563822:0.822848:0.563822:0.822848:0.551547:0.699517:0.551547:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257:0.003257
11.  Team AMM. New MHRA recommendations on simvastatin interac-:@0.519036:0.574984:0.923801:0.574984:0.923801:0.562709:0.519036:0.562709:0.006515:0.006515:0.003257:0.003257:0.005656:0.005009:0.007644:0.008032:0.011030:0.003798:0.008702:0.010807:0.010807:0.003257:0.003786:0.008702:0.007644:0.009772:0.003786:0.010807:0.008032:0.007138:0.008702:0.003798:0.003540:0.007644:0.007608:0.007702:0.011030:0.011030:0.007644:0.007173:0.008055:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003786:0.007702:0.007173:0.003786:0.004563:0.002352:0.011030:0.006515:0.008032:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003810:0.002352:0.007173:0.003986:0.007644:0.003540:0.008032:0.007608:0.003904
tions  – implications for  patients taking  amlodipine &  simvastatin :@0.544236:0.586146:0.927035:0.586146:0.927035:0.573871:0.544236:0.573871:0.003986:0.002352:0.007702:0.007173:0.004563:0.003257:0.002752:0.005880:0.006021:0.002352:0.011030:0.008020:0.002352:0.002352:0.007608:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.006021:0.003692:0.007702:0.003540:0.003257:0.002752:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.006021:0.003986:0.008032:0.005903:0.002352:0.007173:0.007914:0.003257:0.002752:0.008032:0.011030:0.002352:0.007702:0.008055:0.002352:0.008020:0.002352:0.007173:0.007644:0.006021:0.008902:0.003257:0.002752:0.004563:0.002352:0.011030:0.006515:0.008032:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257
40mg/day. New MHRA recommendations. 2012.:@0.544236:0.597308:0.818626:0.597308:0.818626:0.585033:0.544236:0.585033:0.006515:0.006515:0.011030:0.007914:0.005139:0.008055:0.008032:0.006303:0.003257:0.003257:0.008702:0.007644:0.009772:0.003257:0.010807:0.008032:0.007138:0.008702:0.003257:0.003540:0.007644:0.007608:0.007702:0.011030:0.011030:0.007644:0.007173:0.008055:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
12.  Collins R,  Reith C,  Emberson  J,:@0.519036:0.608470:0.730232:0.608470:0.730232:0.596194:0.519036:0.596194:0.006515:0.006515:0.003257:0.003257:0.005656:0.009560:0.007702:0.002352:0.002352:0.002352:0.007173:0.004563:0.006715:0.007138:0.003257:0.003257:0.003445:0.007138:0.007644:0.002352:0.003986:0.007173:0.006715:0.009560:0.003257:0.003257:0.003445:0.006303:0.011030:0.008020:0.007644:0.003540:0.004563:0.007702:0.007173:0.003257:0.003445:0.005668:0.003257
 et  al. :@0.730232:0.608470:0.772177:0.608470:0.772177:0.596194:0.730232:0.596194:0.006715:0.007644:0.003986:0.003257:0.003445:0.008032:0.002352:0.003257:0.003257
Interpretation  of  the  evi-:@0.775634:0.608470:0.923789:0.608470:0.923789:0.596194:0.775634:0.596194:0.002658:0.007173:0.003986:0.007644:0.003540:0.008020:0.003540:0.007644:0.003986:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003445:0.007702:0.003692:0.003257:0.003445:0.003986:0.007173:0.007644:0.003257:0.003445:0.007644:0.006515:0.002352:0.003904
dence for the efficacy and safety of statin therapy. :@0.544236:0.619632:0.846272:0.619632:0.846272:0.607356:0.544236:0.607356:0.008055:0.007644:0.007173:0.007608:0.007644:0.004175:0.003692:0.007702:0.003540:0.004163:0.003986:0.007173:0.007644:0.004175:0.007644:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.004175:0.008032:0.007173:0.008055:0.004175:0.004563:0.008032:0.003692:0.007644:0.003986:0.006303:0.004175:0.007702:0.003692:0.004175:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.004175:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003257:0.003257
Lancet. :@0.847177:0.619632:0.893568:0.619632:0.893568:0.607356:0.847177:0.607356:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257:0.003257
2016; :@0.894473:0.619632:0.927046:0.619632:0.927046:0.607356:0.894473:0.607356:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
388(10059):2532-61.  :@0.544236:0.630794:0.661052:0.630794:0.661052:0.618518:0.544236:0.618518:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257:0.003257:0.003257
 13.  Lwin  EMp,  Ritchie  U,  Gerber  C, :@0.519036:0.641956:0.727739:0.641956:0.727739:0.629680:0.519036:0.629680:0.003257:0.006515:0.006515:0.003257:0.003257:0.002399:0.005433:0.009772:0.002352:0.007173:0.003257:0.001846:0.006303:0.010807:0.006961:0.003257:0.003257:0.001846:0.007138:0.002352:0.003986:0.007608:0.007173:0.002352:0.007644:0.003257:0.001846:0.007702:0.003257:0.003257:0.001846:0.010254:0.007644:0.003540:0.008020:0.007644:0.003540:0.003257:0.001846:0.009560:0.003257:0.003257
et  al.:@0.729608:0.641956:0.759983:0.641956:0.759983:0.629680:0.729608:0.629680:0.007644:0.003986:0.003257:0.001846:0.008032:0.002352:0.003257
  Transfer  of  rosuvastatin into :@0.759983:0.641956:0.927058:0.641956:0.927058:0.629680:0.759983:0.629680:0.003257:0.001846:0.005009:0.003540:0.008032:0.007173:0.004563:0.003692:0.007644:0.003540:0.003257:0.001846:0.007702:0.003692:0.003257:0.001846:0.003540:0.007702:0.004563:0.007150:0.006515:0.008032:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.005115:0.002352:0.007173:0.003986:0.007702:0.003257
breast milk: Liquid chromatography-mass  spectrometry  meth-:@0.544236:0.653117:0.923789:0.653117:0.923789:0.640842:0.544236:0.640842:0.008020:0.003540:0.007644:0.008032:0.004563:0.003986:0.009278:0.011030:0.002352:0.002352:0.005903:0.003257:0.009278:0.005433:0.002352:0.008020:0.007150:0.002352:0.008055:0.009278:0.007608:0.007173:0.003540:0.007702:0.011030:0.008032:0.003986:0.007702:0.007914:0.003540:0.008032:0.008020:0.007173:0.006303:0.003904:0.011030:0.008032:0.004563:0.004563:0.003257:0.006009:0.004563:0.008020:0.007644:0.007608:0.003986:0.003540:0.007702:0.011030:0.007644:0.003986:0.003540:0.006303:0.003257:0.006009:0.011030:0.007644:0.003986:0.007173:0.003904
odology and clinical  recommendations. :@0.544236:0.664279:0.789275:0.664279:0.789275:0.652004:0.544236:0.652004:0.007702:0.008055:0.007702:0.002352:0.007702:0.007914:0.006303:0.007491:0.008032:0.007173:0.008055:0.007491:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003257:0.004245:0.003540:0.007644:0.007608:0.007702:0.011030:0.011030:0.007644:0.007173:0.008055:0.008032:0.003975:0.002352:0.007702:0.007173:0.004563:0.003257:0.003257
Drug Des Devel Ther. :@0.793508:0.664279:0.927070:0.664279:0.927070:0.652004:0.793508:0.652004:0.008749:0.003540:0.007150:0.007914:0.007491:0.008749:0.007644:0.004563:0.007491:0.008749:0.007644:0.006515:0.007644:0.002352:0.007491:0.005009:0.007173:0.007644:0.003540:0.003257:0.003257
2018;12:3645-3651:@0.544236:0.675441:0.645859:0.675441:0.645859:0.663166:0.544236:0.663166:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
14.  Ridker pM, MacFadyen JG, Libby p, Glynn RJ. Cardiovascular bene-:@0.519036:0.686603:0.923777:0.686603:0.923777:0.674328:0.519036:0.674328:0.006515:0.006515:0.003257:0.003257:0.005656:0.007138:0.002352:0.008055:0.005903:0.007644:0.003540:0.002693:0.006961:0.010807:0.003257:0.002693:0.010807:0.008032:0.007608:0.005703:0.008032:0.008055:0.006303:0.007644:0.007173:0.002693:0.005668:0.010254:0.003257:0.002693:0.005433:0.002352:0.008020:0.008020:0.006303:0.002705:0.006961:0.003257:0.002693:0.010254:0.002352:0.006303:0.007173:0.007173:0.002705:0.007138:0.005668:0.003257:0.002693:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.002705:0.008020:0.007644:0.007173:0.007644:0.003904
fits  and  diabetes  risks  of  statin  therapy  in  primary  prevention:  An :@0.544236:0.697765:0.927058:0.697765:0.927058:0.685490:0.544236:0.685490:0.002863:0.002863:0.003986:0.004563:0.003257:0.001881:0.008032:0.007173:0.008055:0.003257:0.001881:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.001893:0.003540:0.002352:0.004563:0.005903:0.004563:0.003257:0.001893:0.007702:0.003692:0.003257:0.001881:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257:0.001881:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003257:0.001881:0.002352:0.007173:0.003257:0.001881:0.008020:0.003540:0.002352:0.011030:0.008032:0.003540:0.006303:0.003257:0.001881:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257:0.001881:0.008702:0.007173:0.003257
analysis from the JUpITER trial. :@0.544236:0.708927:0.713616:0.708927:0.713616:0.696651:0.544236:0.696651:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003692:0.003540:0.007702:0.011030:0.003257:0.003986:0.007173:0.007644:0.003257:0.005668:0.007702:0.006961:0.002658:0.005009:0.006303:0.007138:0.003257:0.003986:0.003540:0.002352:0.008032:0.002352:0.003257:0.003257
Lancet. :@0.713604:0.708927:0.759994:0.708927:0.759994:0.696651:0.713604:0.696651:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257:0.003257
2012;380 (9841):565-71.:@0.759983:0.708927:0.889828:0.708927:0.889828:0.696651:0.759983:0.696651:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
15.  Gupta A, Whitehouse A, Collier T, :@0.519036:0.720089:0.743590:0.720089:0.743590:0.707813:0.519036:0.707813:0.006515:0.006515:0.003257:0.003257:0.005656:0.010254:0.007150:0.008020:0.003986:0.008032:0.004868:0.008702:0.003257:0.004857:0.011289:0.007173:0.002352:0.003986:0.007644:0.007173:0.007702:0.007150:0.004563:0.007644:0.004857:0.008702:0.003257:0.004857:0.009560:0.007702:0.002352:0.002352:0.002352:0.007644:0.003540:0.004857:0.005009:0.003257:0.003257
et al.:@0.745201:0.720089:0.775328:0.720089:0.775328:0.707813:0.745201:0.707813:0.007644:0.003986:0.004857:0.008032:0.002352:0.003257
 AsCOT Investigators. Ad-:@0.775328:0.720089:0.923789:0.720089:0.923789:0.707813:0.775328:0.707813:0.004857:0.008702:0.005856:0.009560:0.010219:0.005009:0.004857:0.002658:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003986:0.007702:0.003540:0.004563:0.003257:0.004857:0.008702:0.008055:0.003904
verse events associated with unblinded, but not with blinded, statin :@0.544236:0.731251:0.927046:0.731251:0.927046:0.718975:0.544236:0.718975:0.006515:0.007644:0.003540:0.004563:0.007644:0.002975:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.002975:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.002975:0.009772:0.002352:0.003986:0.007173:0.002975:0.007150:0.007173:0.008020:0.002352:0.002352:0.007173:0.008055:0.007644:0.008055:0.003257:0.002975:0.008020:0.007150:0.003986:0.002975:0.007173:0.007702:0.003986:0.002975:0.009772:0.002352:0.003986:0.007173:0.002975:0.008020:0.002352:0.002352:0.007173:0.008055:0.007644:0.008055:0.003257:0.002975:0.004563:0.003986:0.008032:0.003986:0.002352:0.007173:0.003257
therapy in the Anglo-scandinavian Cardiac Outcomes Trial-Lipid-:@0.544236:0.742412:0.923789:0.742412:0.923789:0.730137:0.544236:0.730137:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.004668:0.002352:0.007173:0.004680:0.003986:0.007173:0.007644:0.004668:0.008702:0.007173:0.007914:0.002352:0.007702:0.003904:0.005856:0.007608:0.008032:0.007173:0.008055:0.002352:0.007173:0.008032:0.006515:0.002352:0.008032:0.007173:0.004680:0.009560:0.008032:0.003540:0.008055:0.002352:0.008032:0.007608:0.004680:0.010219:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.004668:0.005009:0.003540:0.002352:0.008032:0.002352:0.003904:0.005433:0.002352:0.008020:0.002352:0.008055:0.003904
Lowering Arm (AsCOT-LLA): A randomised double-blind placebo-:@0.544236:0.753574:0.923801:0.753574:0.923801:0.741299:0.544236:0.741299:0.005433:0.007702:0.009772:0.007644:0.003540:0.002352:0.007173:0.007914:0.004516:0.008702:0.003540:0.011030:0.004516:0.004339:0.008702:0.005856:0.009560:0.010219:0.005009:0.003904:0.005433:0.005433:0.008702:0.004339:0.003257:0.004516:0.008702:0.004516:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004563:0.007644:0.008055:0.004516:0.008055:0.007702:0.007150:0.008020:0.002352:0.007644:0.003904:0.008020:0.002352:0.002352:0.007173:0.008055:0.004527:0.008020:0.002352:0.008032:0.007608:0.007644:0.008020:0.007702:0.003904
controlled trial and its non-randomised non-blind extension phase. :@0.544236:0.764736:0.927058:0.764736:0.927058:0.752461:0.544236:0.752461:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003775:0.003986:0.003540:0.002352:0.008032:0.002352:0.003786:0.008032:0.007173:0.008055:0.003786:0.002352:0.003986:0.004563:0.003786:0.007173:0.007702:0.007173:0.003904:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004563:0.007644:0.008055:0.003775:0.007173:0.007702:0.007173:0.003904:0.008020:0.002352:0.002352:0.007173:0.008055:0.003775:0.007644:0.005644:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003775:0.008020:0.007173:0.008032:0.004563:0.007644:0.003257:0.003257
Lancet. :@0.544236:0.775898:0.590626:0.775898:0.590626:0.763623:0.544236:0.763623:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257:0.003257
2017;389:2473-81.:@0.590614:0.775898:0.688980:0.775898:0.688980:0.763623:0.590614:0.763623:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257